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Abstract
Purpose To analyse whether the permeability of the
blood–brain barrier to the antimuscarinic drug trospium
chloride is altered with ageing. This is a relevant question
for elderly patients with overactive bladder syndrome who
are treated with trospium chloride as the occurrence of
adverse effects on the central nervous system (CNS) highly
depends on the absolute drug concentration in the brain.
Methods Trospium chloride at 1 mg/kg was intrave-
nously administered to adult, middle-aged, and aged mice
at 6, 12, and 24 months of age, respectively, and the
absolute drug concentrations in the brain were analysed
after 2 h. Furthermore, mRNA expression levels of rele-
vant markers of blood–brain barrier integrity (occludin,
claudin-5, and the drug efflux carrier P-glycoprotein) were
analysed in brain samples from adult and aged mice.
Results The absolute brain concentrations of the drug
were identical in adult and middle-aged mice (13 ± 2 ng/g
vs. 13 ± 2 ng/g) and were slightly, but significantly, lower
in aged mice (8 ± 4 ng/g). The brain/plasma drug con-
centration ratios were not different between the age groups
and demonstrated the generally low capability of trospium
chloride in permeating the blood–brain barrier. Occludin,
claudin-5, and P-glycoprotein showed identical mRNA
expression levels in the brains of adult and aged mice.
Conclusion Based on our in vivo data in a mouse model,
we conclude that trospium chloride permeation across the
BBB is not increased in ageing per se, and therefore, the
occurrence of adverse CNS drug effects is also not
expected to increase with ageing.
Keywords Trospium chloride  Transport 
Blood–brain barrier  P-glycoprotein  Ageing
Introduction
Antagonists of acetylcholine muscarinic receptors, such as
darifenacin, fesoterodine, oxybutynin, propiverine, soli-
fenacin, tolterodine, and trospium chloride (TCl), are the
cornerstone of pharmacotherapy for the symptoms of
overactive bladder (OAB) [1]. Apart from blocking mus-
carinic receptors in the bladder, most anticholinergic drugs
can cross the blood–brain barrier (BBB) and antagonize the
effects of acetylcholine in the central nervous system
(CNS). In particular, blocking of muscarinic M1 receptors
in the brain was found to be associated with cognitive
impairment, dizziness, and sleep disturbance, which can be
especially detrimental in older patients [2].
Most of the differences in CNS effects of antimuscarinic
drugs can be explained by their different abilities to pen-
etrate through the BBB. While most of the aforementioned
antimuscarinic drugs are tertiary amines that are quite
lipophilic, TCl is a highly polar quaternary amine [3].
Therefore, TCl showed much lower penetration across the
BBB than other more lipophilic antimuscarinic drugs, at
least in mice and rats [4, 5]. The low brain penetration of
TCl was also confirmed in a recent study with older OAB
patients who received extended-release trospium chloride
60 mg once daily over a 10-day period. In these patients,
TCl showed normal peak plasma concentrations of 925
± 478 pg/ml, but was assay undetectable in the cerebro-
spinal fluid (\40 pg/ml) [6].
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Apart from their physicochemical properties, the brain
penetration of antimuscarinic drugs also depends on their
interaction with the drug-transporting P-glycoprotein
(P-gp), which limits the entry of many drugs and xenobi-
otics into the brain by an efflux-based transport mecha-
nism. Recently, we showed that penetration of TCl into the
brain is significantly increased in P-gp-deficient knockout
mice, indicating that P-gp normally restricts the entry of
this drug into the brain [7].
However, the possibility that in elderly patients, who
represent the majority of patients with OAB, the brain
penetration of antimuscarinic drugs might be increased due
to a histological or functional breakdown of the BBB or the
down-regulation of P-gp has been discussed [2, 8]. However,
until now, no clear experimental evidence has been found to
show increased penetration of antimuscarinic drugs into the
brain during ageing. Therefore, in the present study, we
aimed to analyse the absolute brain concentrations of TCl
after its administration to mice of different ages.
Materials and methods
Animals
For drug administration, seven aged (24 months), eight
middle-aged (12 months), and three mature adult (6
months) male and female C57Bl/6N mice were used. For
gene expression studies, we used seven aged (24 months)
and eight adult (6 months) female C57Bl/6N mice as well
as six aged (25 months) and four adult (4 months) male
FVB mice. According to Flurkey et al., mice with
3–6 months of age have a life phase equivalent in humans
of about 20–30 years. Mice with 10–14 months of age
have a human age equivalent of 38–47 years and mice of
18–24 month of age correspond to humans with 59–69
years of age [9]. However, as the survival rate of mice
around 28 month of age is only at about 50%, in the
present study, we grouped 24/25-month-old mice to the
group of aged mice. Nevertheless, several mice died before
they reached the scheduled age of 24/25 months and even
of 12 month. Therefore, the group size varied in the present
study. All of the aged mice showed typical characteristics
of ageing, including a sparse coat and decreased levels of
general activity. The mice were housed in a specific
pathogen-free (SPF) animal facility in isolated ventilated
cages under a controlled temperature with a 12 h/12 h
light/dark cycle. The mice had access to sterilized food and
water ad libitum. All animal experiments were registered
and approved by the local governmental administration and
were conducted in accordance with the Directive 2010/63/
EU of the European Parliament on the protection of ani-
mals used for scientific purposes.
Drug preparation, administration, and tissue
distribution
[3H]Trospium trifluoroacetate (42 Ci/mmol) was pur-
chased from RC TRITEC AG (Teufen, Switzerland), and
unlabelled TCl was kindly provided by Dr. R. Pfleger
GmbH (Bamberg, Germany). The TCl was administered
intravenously at a dosage of 1.0 mg/kg body weight (b.w.)
in all experiments. For each animal, a mixture of [3H]tros-
pium trifluoroacetate (2.5 lCi of the radiolabelled com-
pound) and unlabelled TCl was prepared as described
previously [7]. Due to the high excess of chloride in rela-
tion to trifluoroacetate in the drug preparation, this is fur-
ther referred to as [3H]trospium chloride ([3H]TCl). Two
hours after the administration of [3H]TCl, the mice were
euthanized by cervical dislocation and the organs were
removed and homogenized in 100–2,000 ll 0.05 M KOH,
depending on the tissue weight. The levels of radioactivity
in the blood and in the tissue homogenates were quantified
by a Wallac 1409 liquid scintillation counter.
Gene expression analysis
The mice used for the gene expression studies had not been
used in any other experiment and were euthanized by cer-
vical dislocation. Brain samples were immediately extracted
under sterile conditions and conserved in RNAlater solution
(Applied Biosystems, Darmstadt, Germany). Then, RNA
was isolated using the phenol/chloroform extraction method
using TRI Reagent (Sigma-Aldrich, Taufkirchen, Germany).
Genomic DNA was removed from the RNA preparations by
DNase I digestion (Fermentas, St. Leon-Rot, Germany). The
synthesis of cDNA was performed using the SuperScript III
reverse transcriptase according to the manufacturer’s pro-
tocol (Invitrogen, Karlsruhe, Germany). For quantitative
real-time PCR analysis, the following TaqMan Gene
Expression Assays (Applied Biosystems) were used: Mm0
0440761_m1 for mouse mdr1a (P-gp), Mm00500912_m1
for mouse occludin, Mm00727012_s1 for mouse claudin-5,
and Mm00607939_s1 for mouse beta-actin (endogenous
control). Real-time quantitative PCR was performed with an
ABI PRISM 7300 (Applied Biosystems). Each brain sample
was tested in triplicate in a 96-well optical plate for all targets
using 5 ll cDNA, 12.5 ll TaqMan Gene Expression Mas-
termix, 1.25 ll of the TaqMan Gene Expression Assay
(Applied Biosystems) and 6.25 ll of water in each 25 ll
reaction mixture. No-template controls used water instead of
cDNA for PCR amplification. The plates were heated for
10 min at 95C, and 40 cycles of 15 s at 95C and 60 s at
60C were subsequently applied. The relative expressions of
the analysed genes were determined by subtracting the signal
threshold cycle (CT) value of beta-actin from the CT value of
each analysed gene (DCT).
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Statistical analysis
All data are presented as the mean ± SD. The Student’s
two-tailed unpaired t-test and one-way ANOVA followed
by Bonferroni’s post hoc test were used to identify sig-
nificant differences between the groups.
Results
Brain penetration and tissue distribution of [3H]TCl
in aged mice
[3H]Trospium chloride was administered at a dosage of
1 mg/kg to adult (6 months, n = 3), middle-aged (12
months, male n = 4, female n = 4), and aged (24 months,
male n = 2, female n = 5) C57Bl/6 N mice, and the
absolute drug tissue concentrations were analysed 2 h after
administration. Pooled data for each age group are shown in
Fig. 1a, and an additional gender-specific subanalysis is
given in Table 1. However, as most of the male aged mice
(4 out of 6) died before they reached the scheduled age of
24 months, a statistical gender-specific subanalysis could
not be performed in the group of aged mice. The absolute
drug concentrations were highest in the liver ([1,000 ng/g)
and the kidney ([500 ng/g) but showed no significant dif-
ferences between the age groups in these organs (Fig. 1a).
Drug concentrations among all organs analysed were by far
lowest in the brain (B13 ng/g). As shown in Fig. 1a, sig-
nificantly lower drug concentrations were observed in the
brain of the aged mice compared with the group of the adult
mice (13 ± 2 ng/g vs. 8 ± 4 ng/g). However, in the
gender-specific subanalysis, TCl concentrations in the brain
showed no significant differences (P = 0.1086, Table 1).
Furthermore, the brain/plasma concentration ratios were
nearly identical among the age groups, namely 0.25 ± 0.01
for the adult mice, 0.29 ± 0.12 for the middle-aged mice,
0.24 ± 0.21 for the aged mice.
Apart from the brain, significantly lower drug concentra-
tions were observed in the lung and muscle of the aged mice
compared with the groups of adult and middle-aged mice
(Fig. 1a). This was in part confirmed in the gender-specific
subanalysis (Table 1). Furthermore, drug concentrations in
the blood of the aged female mice were significantly lower
compared with the adult male mice (26 ± 11 ng/ml vs.
71 ± 14 ng/ml) (Table 1). In addition to the comparison of
the different age groups, the gender-specific subanalysis in the
group of middle-aged mice allowed us to directly compare the
tissue distribution and brain penetration of TCl between male
and female mice (Table 1). Among all organs analysed, we
found nearly or even identical drug concentrations in the male
and female mice, particularly in the brain (13 ± 2 ng/g vs.
13 ± 2 ng/g).
P-gp expression pattern in adult and aged mice
Brain samples of 13 aged (24–25 months, male n = 6,
female n = 7) and 12 adult (4–6 months, male n = 4,
female n = 8) untreated mice were used for gene expres-
sion analysis of the drug efflux carrier P-gp (mdr1a) and
the tight junction proteins claudin-5 and occludin by
quantitative real-time PCR. Target mRNA expression was
normalized to the expression of beta-actin. For each real-
time PCR measurement, 50 ng of RNA was used per well
Fig. 1 a Tissue concentrations of [3H]TCl in adult, middle-aged and
aged mice after i.v. administration of 1 mg/kg body weight. Animals
were euthanized 2 h after drug application, and organ drug concen-
trations were determined by liquid scintillation counting. Data
represent means ± SD of three to eight animals per group.
*Significantly different drug concentrations (P \ 0.05). b Relative
mRNA expression levels of the BBB markers mdr1a P-gp, claudin-5,
and occludin in the brain of adult and aged mice analysed by
quantitative real-time PCR
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and revealed very stable CT values for beta-actin of
18.32 ± 0.22 (total range of variation in the absolute CT
values: 18.02–19.10). No significant differences occured in
the beta-actin CT values between the different age groups.
Therefore, beta-actin was a suitable gene for the normali-
zation of the real-time quantification. As shown in Fig. 1b,
the expression levels of mdr1a, claudin-5, and occludin
showed no differences between the adult and aged mice.
Furthermore, gender-specific subanalysis in both age
groups revealed no differences in the expression levels
between the male and female mice (data not shown).
Discussion
Older patients are more likely to experience adverse CNS
effects under drug treatment for several reasons. In the case
of anticholinergic drugs, these have been associated with
cognitive deficits, behavioural changes, and sleep distur-
bance [10]. An increased permeability of the BBB may
contribute to such vulnerabilities. In this regard, it was
claimed that TCl is a safer anticholinergic alternative due
to its generally low permeability across the BBB [11, 12].
However, the age-dependent penetration of trospium
chloride into the brain has never been measured before in
an experimental study.
In the CNS, different barriers exist between blood cir-
culation and neural tissue that have to be considered for
drug permeation into the brain: the blood–brain barrier
(BBB), which is formed by cerebrovascular endothelial
cells, and the blood–cerebrospinal fluid barrier (BCSFB),
which is constituted by epithelial cells of the choroid
plexus [13]. At these interfaces, a barrier function results
from the combination of (I) a histological barrier formed by
tight junction complexes that tightly connect the epithelial
cells and thus greatly limit the paracellular flux of polar
solutes, and (II) a functional barrier comprised of different
transport systems such as P-gp, which regulate the solute
flux across the barrier [14]. Since the surface area of the
BBB is at least 5,000-fold greater than that of the choroid
plexus [15], the BCSFB is only of marginal importance for
the overall drug delivery into the brain. In contrast, abso-
lute drug concentrations in the brain predominantly depend
on the permeability of the BBB, and therefore, this barrier
is the most relevant barrier in the CNS regarding adverse
CNS effects under drug treatment [16].
Several factors can restrict the entry of drugs into the
CNS including a highly polar surface area or a molecular
weight of [450 Da [17]. Additionally, interactions with
drug carriers at the BBB can facilitate or restrict drug entry
into the brain by carrier-mediated uptake or efflux pro-
cesses, respectively [16]. In the case of the anticholinergic
drug TCl, brain penetration is highly restricted by the polar
structure of the molecule and its low lipophilicity, as well as
by a P-gp-mediated drug efflux in the endothelial cells of
the BBB [7]. Therefore, compared with the highly lipophilic
and uncharged drug oxybutynin, TCl showed 200-fold
lower absolute drug concentrations in the brain when
administered at an equal dosage to laboratory mice [4].
In recent reviews about OAB treatment with anticho-
linergic drugs, the fact that the BBB becomes more leaky
with age and so might be more permeable to polar
and P-gp-transported drugs such as TCl was discussed
[2, 8]. Indeed, several age-related changes in the cerebral
Table 1 Drug concentrations of [3H]TCl in tissues (ng/g) and plasma (ng/ml) in adult, middle-aged and aged C57Bl/6N mice 2 h after i.v.
administration of 1 mg/kg
Adult (6 months) Middle-aged (12 months) Aged (24 months)
Male (n = 3) Male (n = 4) Female (n = 4) Male (n = 2) Female (n = 5)
Brain 13 ± 2 13 ± 2 13 ± 2 9 8 ± 5
Liver 1,675 ± 140 1,528 ± 344 1,137 ± 373 1,724 1,756 ± 696
Kidney 660 ± 258 713 ± 271 975 ± 332 279 948 ± 97
Stomach 701 ± 103 735 ± 230 935 ± 332 478 737 ± 752
Lung 117 ± 16 107 ± 30 89 ± 17 101 29 ± 20*
Spleen 68 ± 12 117 ± 26 267 ± 271 91 55 ± 47
Heart 287 ± 60 273 ± 113 226 ± 129 221 202 ± 45
Fat 134 ± 149 56 ± 47 59 ± 35 22 24 ± 14
Muscle 74 ± 24 48 ± 6 39 ± 18 33 33 ± 6**
Blood 52 ± 6 71 ± 14a 40 ± 16 48 26 ± 11a, ***
The data show means ± SD. Significant differences were analysed by one-way ANOVA followed by Bonferroni’s post hoc test except for the
group of aged male mice due to the inadequate group size. * Significantly lower drug concentration compared with all other groups (P \ 0.05);
** significantly lower drug concentration in aged female mice compared with adult male mice (P \ 0.05); *** significantly lower concentration
in aged female mice compared with middle-aged male mice (P \ 0.05)
a Blood samples adequate for analysis could only be obtained for n = 3 mice in these groups
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microvasculature have been reported, including a lower
microvascular density, a smaller capillary lumen size, or
gliofibrillar proliferation [18]. However, whether these
changes actually affect drug penetration across the BBB
has not been analysed. In animal studies with mice and rats,
this question was addressed by studies that administered
[14C]sucrose [19] or higher molecular weight compounds
such as horseradish peroxidase [20]. In general, these
reports showed no significant alteration in BBB perme-
ability with ageing per se. Other studies that analysed the
permeability of the BBB in older human subjects (most of
them by measuring the albumin liquor/plasma ratio) pro-
duced inconsistent results [21]. Although some of these
studies reported an elevation of the albumin liquor/plasma
ratio with ageing, it must be emphasized that this ratio is a
very artificial parameter for the assessment of absolute
drug permeability across the BBB because: (I) alterations
in this ratio primarily indicate a dysfunction of the BCSFB
at the choroid plexus; (II) in terms of physicochemical
properties and drug carrier interactions, albumin is not an
appropriate surrogate for common drugs; and (III) an ele-
vation of the albumin liquor/plasma ratio was previously
shown to be associated with reduced cerebrospinal fluid
production but not with increased albumin permeability at
the BCSFB [22, 23]. Therefore, an increase in the albumin
liquor/plasma ratio during ageing cannot simply be inter-
preted as an increased permeability of the BBB [24, 25].
However, a direct determination of the BBB drug per-
meability and of the absolute drug concentrations in the brain
would require the analysis of brain material after drug
administration, and therefore, such studies can generally not
be carried out on human subjects. Therefore, we decided to
analyse the age-dependent brain penetration of TCl in a
mouse model, with animals ranging from 6 to 24 months of
age. In these mice, the absolute drug concentrations were
directly measured in the brain after a single-dose application
and showed identical levels in the adult and middle-aged
mice (13 ± 2 ng/g) and significantly lower levels in the aged
mice (8 ± 4 ng/g). This slight decline in the brain concen-
tration in the aged mice is probably due to the age-related
changes in the cerebral microvasculature mentioned above.
But due to the generally low drug concentrations in the brain
compared to other organs and the relatively low degree
(13 ± 2 ng/g vs. 8 ± 4 ng/g), this difference is not regarded
as biologically meaningful with regard to the question of CNS
side effects after treatment with antimuscarinic drugs. Fur-
thermore, the brain/plasma concentration ratios for TCl were
not different between the three age groups. Based on these
data, it can be concluded that TCl permeation across the BBB
is at least not increased with ageing per se.
We are aware of the potential limitations of the present study
as the mouse, in terms of lifespan and metabolic activity, is a
somewhat artificial model for the situation in human patients.
Furthermore, this study was designed as a single-dose appli-
cation study with single point detection and cannot directly be
compared to a steady-state distribution after repeated drug
application, which represents the situation in human patients.
Nevertheless, our data are in good agreement with a recent
clinical study in older OAB patients (C65–75 years old) who
received extended-release TCl treatment with 60 mg once
daily over 10 days. These patients underwent memory testing
using the Hopkins Verbal Learning Test-Revised and the Brief
Visuospatial Memory Test-Revised, and showed no significant
drug effects on learning or recall, which can be regarded as very
sensitive parameters of adverse anticholinergic CNS effects.
Furthermore, the TCl drug concentrations in the cerebrospinal
fluid were assay undetectable (\40 pg/ml), with normal peak
concentrations in plasma (*1 ng/ml) [6]. These data clearly
indicate that in older OAB patients, there is no relevant pene-
tration of TCl into the brain under a therapeutic dosage.
Apart from the polar drug TCl, brain penetration studies
have previously been carried out using the more lipophilic
drug verapamil. These studies, using [11C]verapamil positron
emission tomography, found an increase in the distribution
volume in certain, but not all, brain regions [26, 27]. As
verapamil is a well-established substrate of the P-gp efflux
transporter, it was suggested that P-gp might be functionally
down-regulated with ageing. However, studies on human
brain samples showed no influence of age on the cerebro-
vascular expression of the P-gp protein [28]. Even studies on
P-gp expression at the BBB in rodents showed no down-
regulation with age [29], including the present study where
we found identical levels of mRNA expression of P-gp and
the tight junction markers occludin and claudin-5 in mice of
4/6 and 24/25 months of age. We are aware of the fact that the
protein expression level in particular of P-gp might be dif-
ferent, although the mRNA expression level is equal in adult
and aged mice. But as we directly measured the drug entry
into the brain which is significantly dependent on the func-
tional expression of P-gp in the blood–brain barrier [7], we do
not expect that the protein expression of P-gp is significantly
up- or down-regulated in the aged mice.
However, it is possible that barrier functions in the CNS
could be affected by several disease conditions and pathol-
ogies including multiple sclerosis, acute hypertension, cere-
bral ischaemia, diabetes, Alzheimer’s or Parkinson’s disease,
and brain tumours or inflammation [13, 30, 31]. Under these
conditions, impairment of the neurovascular barriers could
range from transient opening of the tight junctions to chronic
barrier breakdown [13, 21]. Additionally, the expression of
drug efflux carriers such as P-gp at the BBB can be affected in
certain diseased conditions such as Alzheimer’s and Parkin-
son’s disease, amyotrophic lateral sclerosis, and inflamma-
tory processes [32]. Therefore, in patients with multiple
co-morbidities, the brain penetration of peripherally acting
antimuscarinic drugs might be increased.
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In conclusion, we demonstrated in a mouse model that
the absolute brain concentrations of the hydrophilic anti-
cholinergic drug TCl were not increased with normal
ageing. Furthermore, we found that, irrespective of the age
of the mice, the brain was the organ with by far the lowest
drug concentrations in the body of the mice, indicating that
the BBB is a very effective permeation barrier against this
drug. Based on our in vivo data, we conclude that TCl
permeation across the BBB is not increased in ageing per
se, and therefore, the occurrence of adverse CNS drug
effects is also not expected to increase.
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